Combined continuous hormone therapy (HT) probably leads to higher breast cancer compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher death from lung cancer compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).
Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).
Hormone replacement therapy (HRT) showed no clear difference in progression‐free survival compared with no HRT (low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of breast cancer compared with no HRT (very low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of transient ischaemic attack compared with no HRT (very low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of cerebrovascular accident compared with no HRT (very low certainty).
It is very uncertain whether hormone replacement therapy (HRT) changes incidence of myocardial infarction compared with no HRT (very low certainty).
The review found no eligible studies for this question.
mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
The review found no eligible studies for this question.
mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).
mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).